Enliven Therapeutics Reports Third-Quarter 2026 Financial Results
Enliven Therapeutics said it aligned with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial and remains on track to start it before year-end. The company reported $884 million in cash, cash equivalents and marketable securities, with cash runway expected into the future.
Story updates
09:07:36 PM UTC
SquawkNews
Enliven said it reached alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial and is on track to initiate it before year-end 2026. Cash, equivalents and marketable securities totaled $884M, expected to fund operations into 2030; no prior-period comparison was provided.Mat…
Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trialOn track to initiate ENABLE-2 before year-end 2026Strong balance sheet with $884 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030BURLINGAME, Calif…